Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05510115 · ClinicalTrials.gov registry record · Phase 2
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
A Phase 2 study of Polycystic Kidney, Autosomal Dominant, sponsored by University of Colorado, Denver.
- Active
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05510115: Active Phase 2 study of Polycystic Kidney, Autosomal Dominant, sponsored by University of Colorado, Denver.
NCT05510115 is a Phase 2 study of Polycystic Kidney, Autosomal Dominant that is active but no longer recruiting, run by University of Colorado, Denver. The registered enrollment target is 50 participants, below the 65-participant average among 4 other Polycystic Kidney, Autosomal Dominant trials with a reported enrollment target (23% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05510115, a Phase 2 study of Polycystic Kidney, Autosomal Dominant, is active but no longer recruiting, sponsored by University of Colorado, Denver.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigator proposes a pilot randomized clinical trial to determine the safety and tolerability of empagliflozin in ADPKD patients. To achieve this, the investigator will conduct a 12-month parallel-group, randomized, double-blind, placebo-controlled trial in 50 ADPKD patients with an eGFR 30-90 mL/min/1.73m2.
Primary Outcome
Safety will be assessed by laboratory testing and recording of adverse events.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Empagliflozin
Study Locations (1)
Colorado
- University of Coloardo Anschutz Medical Campus - Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2022-11-18 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 2 |
What the registry record for NCT05510115 still lists
NCT05510115 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 65-participant average among 4 other Polycystic Kidney, Autosomal Dominant trials with a reported enrollment target (23% lower).
The record links to 1 condition, with Polycystic Kidney, Autosomal Dominant appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05510115 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT05510115 about?
NCT05510115 is a clinical study titled "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease". The investigator proposes a pilot randomized clinical trial to determine the safety and tolerability of empagliflozin in ADPKD patients. To achieve this, the investigator will conduct a 12-month parallel-group, randomized, double-blind, placebo-controlled trial in 50 ADPKD patients with an eGFR 30-9...
What is the current status of trial NCT05510115?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-11-18. Estimated completion is 2026-03-31.
What conditions does trial NCT05510115 study?
This clinical trial studies the following conditions: Polycystic Kidney, Autosomal Dominant.
What interventions are being tested in trial NCT05510115?
The interventions under investigation include: Placebo (DRUG), Empagliflozin (DRUG).
Who is sponsoring clinical trial NCT05510115?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05510115 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Polycystic Kidney, Autosomal Dominant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
COMPLETED · Phase 2
-
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
COMPLETED · NA
-
Effect of Venglustat in Patients With Renal Impairment
COMPLETED · Phase 1
-
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI